Article

Leveraging large-scale biobank EHRs to enhance pharmacogenetics of cardiometabolic disease medications

2024-04-07

Abstract excerpt

Electronic health records (EHRs) coupled with large-scale biobanks offer great promises to unravel the genetic underpinnings of treatment efficacy. However, medication-induced biomarker trajectories stemming from such records remain poorly studied. Here, we extract clinical and medication prescription data from EHRs and conduct GWAS and rare variant burden tests in the UK Biobank (discovery) and the All of Us prog...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 61448599-c080-52d9-a410-ccce209b878f
DOI: 10.1101/2024.04.06.24305415

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Leveraging large-scale biobank EHRs to enhance pharmacogenetics of cardiometabolic disease medicationsDOI 10.1101/2024.04.06.24305415Read

Leveraging large-scale biobank EHRs to enhance pharmacogenetics of cardiometabolic disease medicationsSemantic proximity Read

Separating the genetics of disease, treatment and treatment response using graphical modeling and large-scale electronic health recordsSemantic proximity Read

Biobank Scale Pharmacogenomics Informs the Genetic Underpinnings of Simvastatin Use.Semantic proximity Read

A large electronic-health-record-based genome-wide study of serum lipids.Semantic proximity Read

Biobank scale pharmacogenomics informs the genetic underpinnings of simvastatin useSemantic proximity Read

Metabolomic signatures of lipid-modifying therapies using drug target Mendelian randomizationSemantic proximity Read

Genetic predictors of lifelong medication-use patterns in cardiometabolic diseases.Semantic proximity Read

Characterizing the genetic architecture of drug response using gene-context interaction methods.Semantic proximity Read

A unified framework identifies new links between plasma lipids and diseases from electronic medical records across large-scale cohorts.Semantic proximity Read

Characterizing the genetic architecture of drug response using gene-context interaction methodsSemantic proximity Read

Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisationSemantic proximity Read

Electronic health records: the next wave of complex disease genetics.Semantic proximity Read